Detection of Pancreatic Cancer miRNA with Biocompatible Nitrogen-Doped Graphene Quantum Dots.
cancer detection
fluorescence
gene sensing
graphene quantum dots
miRNA
sensor
Journal
Materials (Basel, Switzerland)
ISSN: 1996-1944
Titre abrégé: Materials (Basel)
Pays: Switzerland
ID NLM: 101555929
Informations de publication
Date de publication:
20 Aug 2022
20 Aug 2022
Historique:
received:
19
07
2022
revised:
17
08
2022
accepted:
17
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Early-stage pancreatic cancer remains challenging to detect, leading to a poor five-year patient survival rate. This obstacle necessitates the development of early detection approaches based on novel technologies and materials. In this work, the presence of a specific pancreatic cancer-derived miRNA (pre-miR-132) is detected using the fluorescence properties of biocompatible nitrogen-doped graphene quantum dots (NGQDs) synthesized using a bottom-up approach from a single glucosamine precursor. The sensor platform is comprised of slightly positively charged (1.14 ± 0.36 mV) NGQDs bound via π-π stacking and/or electrostatic interactions to the negatively charged (-22.4 ± 6.00 mV) bait ssDNA; together, they form a complex with a 20 nm average size. The NGQDs' fluorescence distinguishes specific single-stranded DNA sequences due to bait-target complementarity, discriminating them from random control sequences with sensitivity in the micromolar range. Furthermore, this targetability can also detect the stem and loop portions of pre-miR-132, adding to the practicality of the biosensor. This non-invasive approach allows cancer-specific miRNA detection to facilitate early diagnosis of various forms of cancer.
Identifiants
pubmed: 36013894
pii: ma15165760
doi: 10.3390/ma15165760
pmc: PMC9414703
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : TCU CSE SERC
ID : UG 200601
Organisme : NIH NIBIB
ID : 1 R15 EB031528-01
Références
BMC Genomics. 2007 Jun 12;8:166
pubmed: 17565689
Anal Chem. 2018 Aug 7;90(15):8969-8976
pubmed: 29973048
Anal Biochem. 2017 Apr 15;523:32-38
pubmed: 28159568
Nanomedicine. 2021 Oct;37:102408
pubmed: 34015513
Genes Dev. 2007 Mar 1;21(5):578-89
pubmed: 17344418
Sci Rep. 2017 Aug 25;7(1):9552
pubmed: 28842617
RNA. 2009 Dec;15(12):2375-84
pubmed: 19861428
Sci Rep. 2020 Apr 27;10(1):7074
pubmed: 32341425
Adv Exp Med Biol. 2015;889:71-87
pubmed: 26658997
Biomark Res. 2015 Jun 06;3:12
pubmed: 26120471
Materials (Basel). 2021 Jan 29;14(3):
pubmed: 33572783
Small. 2015 Apr 8;11(14):1620-36
pubmed: 25521301
Cancers (Basel). 2019 Aug 14;11(8):
pubmed: 31416250
F1000Res. 2016 Apr 25;5:
pubmed: 27158468
ACS Appl Mater Interfaces. 2015 Aug 5;7(30):16152-6
pubmed: 26200323
Chem Rev. 2013 Aug 14;113(8):6207-33
pubmed: 23697835
Sci Rep. 2020 Jan 15;10(1):351
pubmed: 31942002
World J Gastroenterol. 2018 May 21;24(19):2047-2060
pubmed: 29785074
Anal Bioanal Chem. 2009 Jun;394(4):1117-24
pubmed: 19132354
Langmuir. 2011 Mar 15;27(6):2731-8
pubmed: 21302946
Biomaterials. 2012 May;33(13):3604-13
pubmed: 22341214
Nanotechnology. 2021 Feb 26;32(9):095103
pubmed: 33126228
Nucleic Acids Res. 2004 Dec 14;32(22):e175
pubmed: 15598818
Front Endocrinol (Lausanne). 2018 Aug 03;9:402
pubmed: 30123182
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Lancet Oncol. 2012 Jun;13(6):e249-58
pubmed: 22652233
Biosensors (Basel). 2020 Nov 20;10(11):
pubmed: 33233700
ACS Biomater Sci Eng. 2019 Sep 9;5(9):4671-4682
pubmed: 33448839
Sci Rep. 2020 Apr 27;10(1):7048
pubmed: 32341400
Nucleic Acids Res. 2005 Nov 27;33(20):e179
pubmed: 16314309
Cancer. 2020 May 15;126 Suppl 10:2379-2393
pubmed: 32348566
Biochem Biophys Res Commun. 2011 Mar 25;406(4):518-23
pubmed: 21329664
Talanta. 2019 May 1;196:563-571
pubmed: 30683406
CA Cancer J Clin. 2020 Sep;70(5):321-346
pubmed: 32729638
Chem Commun (Camb). 2020 Jan 28;56(8):1175-1178
pubmed: 31919487
Nanomaterials (Basel). 2021 Jan 08;11(1):
pubmed: 33435595
Cell. 2004 Jan 23;116(2):281-97
pubmed: 14744438
Br J Cancer. 2021 Mar;124(7):1181-1182
pubmed: 33558710